Latest / Pharmacy Podcast Network / Pharmacists Value in the Clinical Pharmacogenomics Lab with Dr. Jeremy Stuart, Chief Scientific Officer, Precision Genetics | Precision Heal
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:08Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:19Speaker 2: Hey, I'd like to welcome our listeners to the Precision
- 0:22Speaker 2: Health and PGX podcast, which is a podcast that's been
- 0:25Speaker 2: designed specifically for pharmacystem physicians discussing the role of pharmacogenomics
- 0:31Speaker 2: PGX in drug response in the genome. This podcast is
- 0:35Speaker 2: part of the Pharmacy Podcast Network and we're so proud
- 0:39Speaker 2: of Becky Winsload, Doctor Becky Winsload, doctor Benas Serami. They've
- 0:43Speaker 2: been commanding the ship of our PGX focus for three
- 0:48Speaker 2: to four years. Now I'm losing time here and with
- 0:52Speaker 2: the new year coming across twenty twenty five, we're going
- 0:56Speaker 2: to have so much more content around pharmacogenomics, policy discussion,
- 1:01Speaker 2: around disease states conditions.
- 1:03Speaker 1: So we're so excited about this show.
- 1:05Speaker 2: This show one best podcast and the lists through Welt
- 1:09Speaker 2: magazine was listed as the ninth most listened to podcast
- 1:13Speaker 2: on genetics. We're so proud of the accomplishments of Becky
- 1:17Speaker 2: and Benas and with that, here's our next episode.
- 1:23Speaker 3: In a world where one size fits all medications dominate
- 1:27Speaker 3: the pharmaceutical industry. Precision medicine brings a ray of hope
- 1:30Speaker 3: for those seeking customized healthcare. Pharmacists have a unique opportunity
- 1:34Speaker 3: to help people in need of specialized testing to ensure
- 1:37Speaker 3: medications work is intended. Welcome to Precision Help in PGX,
- 1:42Speaker 3: where we unravel the wonders of precision medicine and its
- 1:45Speaker 3: potential to revolutionize the way we approach pharmacy care. Get
- 1:49Speaker 3: ready to uncover the secrets behind pharmacogenomics and how it's
- 1:53Speaker 3: transforming lives. One genome aunt of time.
- 2:05Speaker 1: So I'm our host, doctor Becky Winslow, and you're listening
- 2:09Speaker 1: to the Precision Health in PJS podcast. Just as Todd
- 2:12Speaker 1: mentioned in case you're wondering what happened to the PJX
- 2:16Speaker 1: for Pharmacists podcast, Well you're listening to it right now,
- 2:21Speaker 1: only with a different name and with a goal to
- 2:24Speaker 1: broaden our listenership outside of pharmacy and pharmacist and broadened
- 2:28Speaker 1: our content to include non pharmacogenomics based precision health topics.
- 2:34Speaker 1: My co host Banas Sarami, who's going to introduce herself,
- 2:38Speaker 1: and I decided to rebrand the podcast so potential listeners
- 2:42Speaker 1: wouldn't self exclude themselves from listening based on the podcast name.
- 2:47Speaker 4: Yeah Hey, and I'm Bena's We're super excited about this
- 2:49Speaker 4: new change. No different, like Becky said, than we did
- 2:52Speaker 4: on PJX for Pharmacies podcasts. We'll continue to explore all
- 2:56Speaker 4: things from ecogenomics related, including pharmacist's role in PGA. Our
- 3:00Speaker 4: mission still includes educating and advocating for the broader topic
- 3:04Speaker 4: of precision medicine, so we'll continue to accomplish this mission
- 3:08Speaker 4: to exclusive interviews and with highly qualified and well experienced
- 3:12Speaker 4: industry leaders.
- 3:13Speaker 1: Today's special guest is doctor Jeremy Stewart, chief scientific Officer
- 3:18Speaker 1: and laboratory director for Precision Genetics in South Carolina. Doctor Stewart, welcome,
- 3:24Speaker 1: and please introduce yourself, and please don't be overly humble.
- 3:30Speaker 1: Your pedigree in the laboratory industry is impressive and many
- 3:34Speaker 1: follow you as a key opinion leader. I want our
- 3:37Speaker 1: audience to really realize your education and your accomplishments, and
- 3:42Speaker 1: quite frankly, how you're qualified to talk on this subject.
- 3:45Speaker 5: Thank you, Becky, and thank you for having me. I'm
- 3:48Speaker 5: glad you gave me the prompt not to be humble.
- 3:50Speaker 6: Because I am.
- 3:51Speaker 5: It's very hard on myself, and I don't like really
- 3:55Speaker 5: talking about myself at all, so I appreciate the h
- 3:59Speaker 5: I appreciate that this claimer there. So I'm trained as
- 4:02Speaker 5: a molecular and cellular biologist. I've always loved biology, even
- 4:05Speaker 5: from high school when I was first introduced to me
- 4:08Speaker 5: as a subject, and so I went through my college
- 4:11Speaker 5: career setting that I got in with a laboratory that worked.
- 4:15Speaker 5: It was a trosophola laboratory, but we did some molecular
- 4:18Speaker 5: work as well, And during that time I MI graded
- 4:22Speaker 5: towards the area of public health and where I got
- 4:26Speaker 5: a master's degree in toxicology. One really had nothing to
- 4:29Speaker 5: do with the other, but I happened to be able
- 4:32Speaker 5: to combine those interests of mine and ended up going
- 4:35Speaker 5: doing my PhD work at the Harvard School of Public Health,
- 4:38Speaker 5: and they had a program called Biological Sciences and Public Health.
- 4:42Speaker 5: The idea was to take areas of public health that
- 4:48Speaker 5: were considered pandemics are not pandemics, but epidemics, and devote
- 4:55Speaker 5: laboratory and dedicated laboratory work in that direction. So, for example, cancer,
- 4:59Speaker 5: you could argue that cancer is an epidemic due to
- 5:03Speaker 5: its high frequency and older adults. So I worked in
- 5:07Speaker 5: the area of molecular and cellular biology in cancer.
- 5:10Speaker 6: That was my training, my PhD training.
- 5:13Speaker 5: I did a postdoc at Harvard as well, and I
- 5:16Speaker 5: quickly realized.
- 5:19Speaker 6: That I wanted to.
- 5:20Speaker 5: Try my interests outside academia. Nothing against it, it was
- 5:24Speaker 5: just something I just wanted to spread my wings.
- 5:26Speaker 6: A little bit more. At the time I was young, I.
- 5:30Speaker 5: Could tolerate a higher risk profile, so I decided to
- 5:32Speaker 5: migrate towards startup companies where I felt I could have
- 5:36Speaker 5: more of an impact, perhaps wear a few more hats
- 5:38Speaker 5: as opposed to just being in the laboratory. I certainly
- 5:41Speaker 5: wanted to be in the laboratory, but I also knew
- 5:44Speaker 5: that I had interests in other areas. So I joined
- 5:48Speaker 5: a company in North Boston in Beverly, Massachusetts that ended
- 5:54Speaker 5: up developing one of the commercial next generation sequencing technologies.
- 6:00Speaker 6: And I would love to.
- 6:00Speaker 5: Tell you and your viewers that that was planned and strategic.
- 6:05Speaker 5: But I think anyone who's ever had any success in
- 6:08Speaker 5: startups or in companies in general will tell you that
- 6:10Speaker 5: that there's a development of luck involved and tell you
- 6:14Speaker 5: that I think that's a common thread. There's always hard
- 6:16Speaker 5: work there's always creating opportunity for luck, and I got lucky.
- 6:22Speaker 5: And so the technology, after about two years, was acquired
- 6:26Speaker 5: by Applied Biosystems.
- 6:28Speaker 6: We had to.
- 6:29Speaker 5: Scale it, commercialize it, put it into the field, send
- 6:32Speaker 5: it to these genome centers that love to take what
- 6:35Speaker 5: you've created and look at it very carefully and then
- 6:38Speaker 5: promptly break it over.
- 6:39Speaker 6: Their knee if you do so.
- 6:42Speaker 5: But that was a wonderful experience because I really got
- 6:44Speaker 5: to migrate from a research and development environment into applications.
- 6:49Speaker 5: And that was my really first foray into clinical science
- 6:53Speaker 5: and clinical laboratory work, where a lot of these genome
- 6:56Speaker 5: centers would do pre validation work, test the limits of
- 7:01Speaker 5: the systems, and then as it as it matured, migrated
- 7:05Speaker 5: into the clinical labs.
- 7:06Speaker 6: And that's what happened with the technology as well.
- 7:08Speaker 5: It just like a computer, how they get smaller and
- 7:11Speaker 5: faster and cheaper over time. So this technology and when
- 7:15Speaker 5: it does that, it can migrate into the clinical the
- 7:18Speaker 5: clinical space. So my career took a turn when that happened,
- 7:22Speaker 5: because I started going to a lot of hospital systems,
- 7:25Speaker 5: visiting with a lot of physicians showing these technologies, and
- 7:29Speaker 5: around that time, that's when the CPT codes for PGX
- 7:35Speaker 5: or for pharmacal genetic related genes were published and released.
- 7:41Speaker 5: By that time, I had joined a clinical I went
- 7:44Speaker 5: back into startup mode and joined a clinical laboratory that
- 7:48Speaker 5: was working with a hospital system mainly in the area
- 7:50Speaker 5: of oncology. But because these PGX related codes have been released,
- 7:55Speaker 5: there was a lot of opportunity in that area and
- 7:59Speaker 5: we quickly adopted that into our toolkit. So again it
- 8:06Speaker 5: was partially luck, partial just happenstance, but I became a
- 8:11Speaker 5: first hand developer and user and expert in this area
- 8:16Speaker 5: and it sort of carried me to where I am
- 8:18Speaker 5: today through two different companies. I've learned a lot of
- 8:21Speaker 5: lessons along the way. It's been a lot of it's
- 8:23Speaker 5: been a lot of fun. I've had a lot of
- 8:24Speaker 5: interactions with with physicians and really got to know the
- 8:27Speaker 5: clinical side. And you know, it's sort of led me
- 8:33Speaker 5: to speaking to you today about done. So what I
- 8:37Speaker 5: do typically is, you know, I'll validate the assays. Again,
- 8:40Speaker 5: I'm a scientist, that's sort of my training and my identity. Again,
- 8:45Speaker 5: I wear a lot of other hats. I've been able
- 8:48Speaker 5: to get board certified in the meantime, so I can
- 8:51Speaker 5: act as a high complexity clear director, laboratory director. I
- 8:55Speaker 5: do that as as one of my hats and on
- 8:57Speaker 5: the business development side, but real my my first love
- 9:01Speaker 5: is to develop these assays, to work in the laboratory,
- 9:04Speaker 5: to validate them, to make sure that the laboratory is
- 9:07Speaker 5: operating as best as possible, and then serve as the
- 9:11Speaker 5: bridge to physicians to talk about the science, how they
- 9:13Speaker 5: can how they can use it clinically.
- 9:16Speaker 1: Wow, what a what a fun story, what a great story.
- 9:21Speaker 1: You're exactly right. I think that, for example, Banasa and
- 9:25Speaker 1: I both took a non traditional pathway. I don't think
- 9:27Speaker 1: we could have planned it when we graduated that this
- 9:30Speaker 1: is where we would be today, but we love it
- 9:32Speaker 1: and here we are.
- 9:36Speaker 6: Life, you know, you is what's the saying? You know?
- 9:39Speaker 6: Life is? Life is what happened to you when you're
- 9:41Speaker 6: making plans? You know right?
- 9:43Speaker 1: Exactly My best laid plans, Uh, well took some turns
- 9:48Speaker 1: and here I am and I love it. So so
- 9:51Speaker 1: I appreciate you giving our audience your backstory and especially
- 9:56Speaker 1: how you got into pharmacogenomics. And so you and I
- 10:02Speaker 1: spoke prior to this recording, and I love what you
- 10:07Speaker 1: had to say about the importance of pharmacists. So today
- 10:13Speaker 1: we're just discussing a topic that I've wanted to cover
- 10:16Speaker 1: on the podcast for a while, and that is pharmacists
- 10:19Speaker 1: value in clinical pharmacogenomics lab. And I just want to
- 10:24Speaker 1: be clear before we go forward that I'm not referring
- 10:28Speaker 1: to pharmacist's value and incorporating pharmacogenomics into medication therapy management
- 10:35Speaker 1: and for example, establishing, launching, evaluating, consulting, and leading clinical
- 10:41Speaker 1: pharmacogenemics delivery in clinical settings you know, such as hospitals,
- 10:46Speaker 1: long term cares, and ambulatory care where we most often
- 10:51Speaker 1: think of pharmacists practicing. Today, we're really focusing on the
- 10:57Speaker 1: pharmacist laboratory. The pharmacists we're talking about today works for
- 11:04Speaker 1: the clinical laboratory as a team member to optimize clinical
- 11:08Speaker 1: PGS testing at the lab level in the PGX testing workflow.
- 11:14Speaker 1: So I'm so excited for you to join us today
- 11:17Speaker 1: and share your first hand experiences honestly with employee and
- 11:22Speaker 1: a pharmacist in your laboratory and you know, providing us
- 11:26Speaker 1: some specific examples to illustrate how vital that pharmacist was
- 11:32Speaker 1: to your lab.
- 11:34Speaker 6: Yeah.
- 11:34Speaker 5: Absolutely, so you know, it became very clear as we
- 11:39Speaker 5: progress in our testing and our engagement with physicians that
- 11:43Speaker 5: having a real clinical expert, especially in the area, in
- 11:49Speaker 5: the area of pharmacy or so so a farm dye
- 11:52Speaker 5: will be very was very important, not to just the
- 11:55Speaker 5: physician engagement, which.
- 11:56Speaker 6: Is a critical role as well as the.
- 12:00Speaker 5: Business development, but also to the laboratory because there's there's
- 12:05Speaker 5: you know, for those who don't know many of the
- 12:07Speaker 5: laboratories who do this type of testing, you know, they're
- 12:10Speaker 5: very sophisticated experts in their area, which is running the
- 12:15Speaker 5: lab validating a test. What they may not be expertise
- 12:20Speaker 5: in is the relationship between the genes and the drugs.
- 12:24Speaker 5: What drugs are are currently being used that have gene
- 12:27Speaker 5: drug relationships that have that rise to a level of
- 12:30Speaker 5: evidence that that we can report on and provide guidance on.
- 12:35Speaker 5: You know, a lot of people in the laboratory just say, well,
- 12:38Speaker 5: just tell me what genes to test and i'll and
- 12:39Speaker 5: I'll at work. Right. Yes, they don't have that sort
- 12:43Speaker 5: of clinical you know, they don't necessarily look at that
- 12:47Speaker 5: pipeline coming through and you know that's where a farm
- 12:52Speaker 5: d has been very important for us. Is to look at,
- 12:55Speaker 5: you know, what's on the horizon, what's the current state
- 12:57Speaker 5: of the evidence. And the other aspect of it is
- 13:02Speaker 5: the actual report itself. So again, if you're a provider
- 13:06Speaker 5: of these tests, so what I mean is a laboratory
- 13:08Speaker 5: typically one of the most important components is not necessarily
- 13:12Speaker 5: that well, certainly the test itself and the analytes that
- 13:16Speaker 5: are in the test, but the report. What does the
- 13:19Speaker 5: report say, how is it organized, how long is it
- 13:22Speaker 5: what does it emphasize?
- 13:24Speaker 6: You know, that's a lot of that's a lot.
- 13:27Speaker 5: It's a big area where a laboratory, if they're providing
- 13:30Speaker 5: that report, needs guidance, and a farm DA has really
- 13:35Speaker 5: been helpful in that process. I can give a few
- 13:38Speaker 5: a specific example of how reports how that input has
- 13:43Speaker 5: helped us configure our reports. But that's a really another
- 13:45Speaker 5: important area that has been extremely helpful.
- 13:50Speaker 6: A lot of these assays.
- 13:52Speaker 5: You know, the technology providers I like to call them
- 13:54Speaker 5: arms dealers.
- 13:58Speaker 6: You know, they.
- 13:58Speaker 5: Developed these assays in house, so a lot of them
- 14:02Speaker 5: are pre configured, and many labs can get up and
- 14:04Speaker 5: running with the PGX test.
- 14:06Speaker 6: You know, as long as you have the requisite.
- 14:08Speaker 5: Expertise and the laboratory and the compliance and you can
- 14:10Speaker 5: operate a clear laboratory.
- 14:13Speaker 6: You can you know, you can go pretty far in
- 14:15Speaker 6: terms of getting a test up and running.
- 14:18Speaker 5: Really where a lot of the art is and a
- 14:20Speaker 5: lot of the domain expertise relies in is again the
- 14:23Speaker 5: development of novel markers and genes, regulationships and looking at
- 14:27Speaker 5: the current state of the literature and consensus recommendations. But
- 14:31Speaker 5: also how is the report translated, or how is the
- 14:36Speaker 5: report provided to the physician, what does it say? How
- 14:40Speaker 5: long is it again, how is it organized? Those are
- 14:44Speaker 5: real things that make a huge difference, and that often
- 14:48Speaker 5: is a black box to the laboratory teams because they
- 14:51Speaker 5: just don't have that clinical side or that clinical expertise
- 14:55Speaker 5: of what's really important to a physician. And I don't
- 14:59Speaker 5: think a lot of people appreciate how busy physicians are.
- 15:02Speaker 1: That's right exactly.
- 15:04Speaker 5: If yeah, if you have a thirty page report and
- 15:07Speaker 5: you have to find the drug that you're looking for
- 15:12Speaker 5: guidance on on paging, it's probably not going to be,
- 15:17Speaker 5: you know, a thing that is adopted widely by physician practice.
- 15:22Speaker 5: So that's really where a lot.
- 15:24Speaker 6: Of that input comes in, and it's been extremely helpful for.
- 15:29Speaker 1: Us Yeah, I couldn't agree more. That's one of the
- 15:34Speaker 1: instrumental roles I've played with labs is with that test
- 15:38Speaker 1: report design and making it physician friendly, because you're exactly right,
- 15:48Speaker 1: we expect physicians to embrace a test that they didn't
- 15:54Speaker 1: necessarily learn about in school. They might not necessarily know
- 15:59Speaker 1: how to act on the results, and we're handing them
- 16:03Speaker 1: this massive thirty page report expecting them to act on it,
- 16:08Speaker 1: and like you said, they just they don't have that
- 16:10Speaker 1: type of time in their workflows these days. It just
- 16:16Speaker 1: doesn't happen. And maybe accept in select situations. That's an
- 16:21Speaker 1: excellent point, an excellent point. The clinical perspective and helping
- 16:26Speaker 1: the lab to understand the clinical presentation of the information
- 16:34Speaker 1: is critical.
- 16:35Speaker 6: Yeah, absolutely, absolutely, yeah.
- 16:38Speaker 4: And it's a different language that has used now that
- 16:41Speaker 4: needs to be learned. So I appreciate that you see
- 16:43Speaker 4: the value of farm D's bringing on to your lab.
- 16:47Speaker 4: But is there specific credentials obviously outside of farm D
- 16:52Speaker 4: like experience that you would you think, based on what
- 16:56Speaker 4: you're seeing now, that they would need to have coming
- 16:59Speaker 4: into your lab side of just a farm D like
- 17:01Speaker 4: is it should they have worked with genetic genetics before like,
- 17:06Speaker 4: what does that look like based on your knees of
- 17:08Speaker 4: the lab.
- 17:09Speaker 5: It's that's a that's a good question. I wouldn't say
- 17:13Speaker 5: specific credentials per se, but it does certainly help. What's
- 17:17Speaker 5: been fun for me is to watch the interaction and
- 17:19Speaker 5: watch the farm d's learn as much as I've seen
- 17:21Speaker 5: the lab learn from the ds. Right, So there's a
- 17:24Speaker 5: true ying and yang that is that I think if
- 17:27Speaker 5: you have a good organization and good collaboration, that both sides.
- 17:31Speaker 6: Learn a lot.
- 17:32Speaker 5: So, for example, you know, a lot of farm d's
- 17:35Speaker 5: in my experience, you know pg X is you know,
- 17:39Speaker 5: I think, being taught in a lot of pharmacy schools,
- 17:42Speaker 5: but it is an elective right in many places, and
- 17:45Speaker 5: it's not necessarily part of a core curriculum. So a
- 17:48Speaker 5: lot of farm d's this is new to them, believe
- 17:50Speaker 5: it or not, certainly with physicians, so they're not familiar
- 17:54Speaker 5: with diplotypes and and you know, uh, you know, diplotype
- 17:58Speaker 5: phenotype relationships. So it's been fun to watch some of
- 18:02Speaker 5: our the farm ds that we work with learn about
- 18:06Speaker 5: this and really be eager about it. And of course
- 18:08Speaker 5: it helps them get a running start if they have
- 18:12Speaker 5: a little bit of that background and a little bit
- 18:14Speaker 5: of that training, even if it's just in a classroom.
- 18:18Speaker 5: A lot of the other things too, you know, things
- 18:20Speaker 5: like feeno conversion if they're on like a two D
- 18:22Speaker 5: six inhibitor, and a lot of reports don't have that
- 18:25Speaker 5: sophistic aren't sophisticated enough to provide that that translation or
- 18:29Speaker 5: provide that input. But you know, a farm D if
- 18:31Speaker 5: they look at a current medication regimen, can provide that
- 18:36Speaker 5: feedback and provide that feedback to the laboratory to say, guys,
- 18:40Speaker 5: is there a way that you can code?
- 18:41Speaker 6: You know, because is there a way they can get
- 18:42Speaker 6: a report that that would.
- 18:44Speaker 5: Provide that information right off the bat rather than relying
- 18:46Speaker 5: on so so it's really been helpful to have some
- 18:54Speaker 5: farm d's that have that experience. Most of it has
- 18:59Speaker 5: been practical variance, you know, especially pharma d's who've worked
- 19:02Speaker 5: with hospital systems and physicians in trying to implement pgfs.
- 19:05Speaker 6: But having said.
- 19:07Speaker 5: That, I've also had really good success with just because
- 19:12Speaker 5: they have such a foundational knowledge of medications and inating
- 19:16Speaker 5: with physicians. Believe it or not, the genetics part is
- 19:19Speaker 5: actually I think the genetics part and and you know, diplotype,
- 19:22Speaker 5: phenotype translations and things of that sort are easier to
- 19:25Speaker 5: learn than the other.
- 19:26Speaker 6: Way around than learning part of it and all the medications.
- 19:30Speaker 5: So so I think any farm D would would really
- 19:34Speaker 5: as long as there are an interest in a passion,
- 19:36Speaker 5: I think would do very well, as long as they
- 19:38Speaker 5: have that communication with the laboratory set up.
- 19:43Speaker 6: And we really try to to make sure that that happens.
- 19:45Speaker 5: So we'll have you know, weekly meetings, aporature meetings where
- 19:49Speaker 5: we include the farm D in our discussions and.
- 19:52Speaker 6: Just sort of by that just by being part.
- 19:54Speaker 5: Of that and osmosis, so you just learn a lot
- 19:58Speaker 5: and then say, the same goes the other way with
- 20:00Speaker 5: the laboratory and when they talk about the engagements and
- 20:04Speaker 5: and a farm these feedback on the reports and also
- 20:08Speaker 5: on you know, upcoming drugs. So I mean a great
- 20:11Speaker 5: ext is GOP one agonists, right, Yes, you know everyone's
- 20:15Speaker 5: asking about you know, well, can you provide guidance on those?
- 20:18Speaker 6: And and you know farm des will have a lot
- 20:22Speaker 6: to say about.
- 20:22Speaker 1: That, Yes, that that could be a topic for an
- 20:25Speaker 1: entire other episode GEO. Yeah, GOEP variants and what evidence
- 20:33Speaker 1: exists and what evidence we need uh to have that
- 20:37Speaker 1: as a test option.
- 20:39Speaker 6: Yeah, definitely.
- 20:41Speaker 4: Did the pharmacists have a specific department in the lab
- 20:45Speaker 4: they work like such as medical information or communication like marketing.
- 20:50Speaker 4: I know, market access and reinverorsement is huge. Like for example,
- 20:54Speaker 4: I worked in the medical affairs department as an MSL,
- 20:57Speaker 4: but obviously supported cross functionally the market team to develop
- 21:01Speaker 4: clinical content. So do you have a specific department that
- 21:05Speaker 4: you assigned pharmacists or kind of They all wear multiple
- 21:08Speaker 4: has depending on the need.
- 21:10Speaker 6: Yeah, you know, based on what our needs as a company.
- 21:13Speaker 5: You know, where we put our farm D's was really
- 21:17Speaker 5: on the commercial side, which is just a function of
- 21:20Speaker 5: how our organization is structured.
- 21:22Speaker 6: So they did a lot.
- 21:23Speaker 5: Of course, physician engagement was a big part of it,
- 21:25Speaker 5: and the business development side, which is to go to
- 21:28Speaker 5: various physician practices that were either using our test or
- 21:32Speaker 5: considering it or had colleagues who are using it and
- 21:35Speaker 5: then talking about it and relating to them on a
- 21:38Speaker 5: peer to peer level. So in our organization there was
- 21:42Speaker 5: a there. From an org structure standpoint, they were on
- 21:45Speaker 5: the commercial side. But having said that, there was so
- 21:50Speaker 5: much interaction with the laboratory teams and with the development
- 21:56Speaker 5: teams and the I side on the IT side, you know,
- 22:00Speaker 5: because of the report structure and that feedback.
- 22:03Speaker 6: Is that there was a lot of crosstalk, you know.
- 22:06Speaker 5: So from a formal organization perspective, you know, yeah, they
- 22:09Speaker 5: were on the commercial side, but from a day to day,
- 22:12Speaker 5: you know, logistics interactive perspective, there's a lot of crosstalk.
- 22:15Speaker 5: And I think, I think you really you're underutilizing your
- 22:18Speaker 5: farm D and your organization if they're not doing those
- 22:21Speaker 5: multiple interactions with different groups, because I think there's just
- 22:25Speaker 5: so much good feedback to have from a farm D
- 22:30Speaker 5: that again is new to so many people, especially a
- 22:33Speaker 5: laboratory organization m.
- 22:36Speaker 7: This episode is brought to you by Thermo Fisher Scientific.
- 22:39Speaker 7: Go from treat and wait to test and tailor. Use
- 22:43Speaker 7: genetic testing to research how to help patients get the
- 22:45Speaker 7: right medication dose for them at the right time the
- 22:49Speaker 7: first time. Pharmacogenomics PGX has the potential to help reduce
- 22:54Speaker 7: healthcare costs and help protect lives. Physicians and pharmacists can
- 22:58Speaker 7: support the movement to integrate pg X end of the
- 23:00Speaker 7: standard of care so patients can get tailored treatment with
- 23:04Speaker 7: fewer adverse reactions. Thermal Fisher Scientific has been helping to
- 23:07Speaker 7: drive PGX research for over a decade, and we continue
- 23:11Speaker 7: to invest and participate in collaborations to help make it
- 23:14Speaker 7: accessible and affordable. Explore pharmacogenomics at ThermoFisher dot com slash
- 23:19Speaker 7: PGX education.
- 23:22Speaker 1: I'm really glad you brought that point up that you know,
- 23:26Speaker 1: although you know, structurally in the organization we can characterize
- 23:30Speaker 1: them with a job title of farmedy, with a job
- 23:32Speaker 1: title or a department, they're really valuable across the company
- 23:38Speaker 1: or across the lab for helping in various different scopes
- 23:43Speaker 1: like you said, I mean, for example, one of the
- 23:45Speaker 1: places where I think labs have appreciated me the most
- 23:48Speaker 1: is on that commercial side, where I help the business
- 23:53Speaker 1: development and sales team understand how to talk to prescribers'
- 23:59Speaker 1: pain points and letting them know what they're up against
- 24:03Speaker 1: in the field when they're trying to sell this product
- 24:07Speaker 1: to a physician who maybe overworked and understaffed or has concerns,
- 24:13Speaker 1: but helping them understand the psychology behind it and helping
- 24:17Speaker 1: them to overcome, you know, what they might run up
- 24:21Speaker 1: against in the field so that they're more successful. And
- 24:25Speaker 1: I think that's that I know that's one of the
- 24:28Speaker 1: things that they've appreciated most, uh, you know that I've
- 24:32Speaker 1: done when I've been working with LAPS.
- 24:34Speaker 6: Yeah.
- 24:35Speaker 5: And on the commercial side, well, and there's a customer
- 24:38Speaker 5: service element too. Again that's another department or another you
- 24:42Speaker 5: know arm that I failed to mention where they are
- 24:45Speaker 5: doing a lot of work in which is again a
- 24:49Speaker 5: lot of physicians, you know, when they see their first
- 24:51Speaker 5: pg EX report, you know you kind of see their
- 24:54Speaker 5: eyes get big, and you know they're intimidated. And I
- 24:57Speaker 5: understand that because you know many of them. It's not
- 25:01Speaker 5: like a medication action plan where it's like a couple
- 25:03Speaker 5: of sentences, right, or it's a it could be a
- 25:08Speaker 5: eighteen to twenty to thirty page report, you know, with
- 25:11Speaker 5: a lot of information, and so just having somebody who
- 25:14Speaker 5: can kind of guide them the first time through it
- 25:18Speaker 5: and just say, look, this is how I look at this.
- 25:21Speaker 5: You know, this is this is what I look out for,
- 25:23Speaker 5: this is what this section means, and you don't you
- 25:24Speaker 5: don't need to worry about this or that or and
- 25:28Speaker 5: really goes a long way, and it really drives the
- 25:31Speaker 5: utilization of the test among providers because once they once
- 25:36Speaker 5: they see it once or twice and have someone to
- 25:38Speaker 5: talk to about it, they become much more comfortable because
- 25:42Speaker 5: I thought, you know, we talk about precision medicine a
- 25:45Speaker 5: lot and how it's such a wonderful thing and physicians
- 25:48Speaker 5: everyone with precision medicine. The thing is is not a
- 25:51Speaker 5: lot of people do it right right outside of oncology, right,
- 25:56Speaker 5: and so so you know, you really need that engagement
- 26:01Speaker 5: and handholding at least at first to get them to
- 26:03Speaker 5: a place where you know, they can walk.
- 26:05Speaker 1: On their own right. And I mean that is in
- 26:08Speaker 1: my experience, that customer service that you're describing will make
- 26:12Speaker 1: or break the success of a PGX test. Had a
- 26:17Speaker 1: medical director tell me once that we were not going
- 26:20Speaker 1: to do the doctor's work for them and so we
- 26:23Speaker 1: would not be fielding those types of calls, and I
- 26:26Speaker 1: thought to myself, oh gosh, oh well, we'll see how
- 26:32Speaker 1: this goes. I could see it coming full steam ahead.
- 26:41Speaker 1: And needless to say, the prescribers continue to ask for
- 26:45Speaker 1: help and that's what they wanted, and well, yes, we
- 26:50Speaker 1: won't go there. We know the end of that story.
- 26:57Speaker 1: And I think Benas has done a lot of work
- 26:59Speaker 1: in that area, you know, with the labs she's worked
- 27:02Speaker 1: with in that right, Vinas, Yeah, definitely for sure.
- 27:08Speaker 5: But you know, if you don't mind, I can give
- 27:10Speaker 5: a specific example on the report side, on the proper
- 27:14Speaker 5: side of you know how a farmbee was so useful
- 27:17Speaker 5: to us.
- 27:18Speaker 6: It was one of those moments that.
- 27:22Speaker 5: We just thought, well, that should have been obvious, right,
- 27:26Speaker 5: you know, but just coming from a laboratory and a
- 27:29Speaker 5: non clinical background, you just don't think of it. So,
- 27:32Speaker 5: you know, we have a psychotropic report that lists medications
- 27:37Speaker 5: related to mental health, antidepressants, anti anxiety medications, antipsychotics.
- 27:44Speaker 6: And you'll notice this with many reports, but it lists them.
- 27:47Speaker 6: You know, you do what makes sense? Right, Oh, I'll
- 27:50Speaker 6: just list it in alphabetical.
- 27:51Speaker 5: Order, right, And so you've got antidepressants miss mixed with
- 27:56Speaker 5: ADHD and you've got you know, you've got just a
- 27:58Speaker 5: whole list of medications lists to an alphabetical order. And
- 28:01Speaker 5: that from a coding perspective, that makes the developer's life easier.
- 28:04Speaker 6: So why not do.
- 28:06Speaker 5: And so you know our farm you looked at this
- 28:09Speaker 5: and said, you really need to change this.
- 28:13Speaker 6: I'll due respect.
- 28:14Speaker 5: And what you want to do is you want to
- 28:16Speaker 5: organize these drugs by class and subclass.
- 28:20Speaker 6: You want to try to reflect how a.
- 28:22Speaker 5: Physician would in this area of mental health would actually
- 28:27Speaker 5: go to their tool bag first, second, third, you know,
- 28:30Speaker 5: for example, you know, in the area of antidepressants, you
- 28:33Speaker 5: list snri's first, SSRI's second, you know, eighty third, TCA's last,
- 28:40Speaker 5: and then if you want to go alphabetical within those classes, great,
- 28:43Speaker 5: go for it, right.
- 28:45Speaker 6: First versus second generation antipsychotics.
- 28:49Speaker 5: You know, list those in particular order, because you don't
- 28:52Speaker 5: want anyone you know, many of these reports have a
- 28:54Speaker 5: stoplight motif right where it's the red, yellow, green, that's
- 28:57Speaker 5: very common.
- 28:59Speaker 6: You don't want anyone to be steered towards a particular
- 29:01Speaker 6: color just because it's a color.
- 29:03Speaker 5: Right, You want to clinical background and expertise first, and
- 29:08Speaker 5: then look towards the gene drug relationship and howation you
- 29:13Speaker 5: know there. And that was sort of just an AHA
- 29:15Speaker 5: moment for us because it just made so much sense
- 29:18Speaker 5: and it seems so simple on the surface, but you'd
- 29:21Speaker 5: be surprised, right, you know what you see when you
- 29:25Speaker 5: look at a lot of the work solutions that are
- 29:27Speaker 5: out there. So that was a real I mean, that
- 29:29Speaker 5: was a that was a real defining moment in the
- 29:33Speaker 5: utility of having that type of feedback on the report
- 29:37Speaker 5: and that and that that affected things dramatically for us.
- 29:40Speaker 1: We appreciate that specific example, and I mean you're exactly right.
- 29:45Speaker 1: It's you know, we both contribute uh vital parts of
- 29:50Speaker 1: this process, the laboratory side and then what the farm
- 29:53Speaker 1: d brings. But helping each other see their blind spots
- 29:58Speaker 1: is I'd say absolutely one of the best things that
- 30:01Speaker 1: comes out of this relationship is helping reveal those blind
- 30:07Speaker 1: spots that we might not be aware that we have.
- 30:11Speaker 4: Yeah, and the other important thing is all the things
- 30:14Speaker 4: of the pharmacists you said brings on board and special
- 30:17Speaker 4: projects that you guys have them do. I know you
- 30:21Speaker 4: gave a couple example, but just wondering if any one
- 30:24Speaker 4: of them really stands out that's very impactful to your lab. So,
- 30:27Speaker 4: for example, you know, an advisory board is important since
- 30:32Speaker 4: that's where you get the feedback from individuals that use
- 30:35Speaker 4: their product or a competitor that made may be using
- 30:39Speaker 4: a competitor product and they can see give better insight
- 30:42Speaker 4: in the clinical utility of that and what they want
- 30:45Speaker 4: to see that makes it different and more valuable to
- 30:48Speaker 4: them utilizing it, and then compare that to the competitor
- 30:51Speaker 4: so they call it advisory board, but you can call
- 30:54Speaker 4: it whatever you want, because you know, every lab is different.
- 30:57Speaker 4: But is there kind of a special project that stands
- 31:00Speaker 4: out that was impactful or do you have those advisory
- 31:04Speaker 4: board quote unquote.
- 31:06Speaker 5: Yeah there but yeah, so we have a couple I
- 31:10Speaker 5: can answer that a couple of different ways. So, you know,
- 31:13Speaker 5: we one of the things that we're very interested in
- 31:16Speaker 5: doing is pushing the research, pushing the knowledge base of
- 31:21Speaker 5: pg X and how.
- 31:21Speaker 6: It can be used.
- 31:22Speaker 5: And one of the areas that I personally think that
- 31:25Speaker 5: is underutilized I could have a big impact, as in
- 31:27Speaker 5: the area of perioperative medicine.
- 31:29Speaker 6: So if you think about.
- 31:32Speaker 5: Your experience when you go through a surgical procedure, you know,
- 31:36Speaker 5: you're you're given an anesthetic, you're given a pain medication.
- 31:39Speaker 5: Post operatively, you're probably giving an anti medic as well
- 31:43Speaker 5: in your a very vulnerable state, right, maybe an anti
- 31:47Speaker 5: coagulant you know as well. So there's a within a
- 31:50Speaker 5: very short window, there are a lot of medications that
- 31:54Speaker 5: could be thrown at you and that can make a
- 31:59Speaker 5: big difference and how you respond to how much time.
- 32:01Speaker 6: You spend in the pack you.
- 32:04Speaker 5: Given the fact that you know, surgeries are a huge
- 32:08Speaker 5: source of revenue for hospital systems.
- 32:10Speaker 6: The portion you can be.
- 32:11Speaker 5: The better patient experiences you have, that's that's going to
- 32:14Speaker 5: have a big impact on a hospital system. So we
- 32:16Speaker 5: really wanted to push that area, and so we had
- 32:23Speaker 5: drafted and submitted a research protocol clinical study for in
- 32:30Speaker 5: the area of perioperative perioperative medicine to an i r B,
- 32:34Speaker 5: and in that we one of the things that we
- 32:36Speaker 5: had learned and we just we didn't publish this or
- 32:38Speaker 5: even presented an abstract of it, is that one of
- 32:41Speaker 5: the things we learned is that when it came to the.
- 32:44Speaker 6: Utilization of pg X reports and what they.
- 32:48Speaker 5: Say, if we had a farm D involved in that process,
- 32:52Speaker 5: that's sort of that feedback loop to the physician we
- 32:56Speaker 5: are uptake. Again, this is just internal numbers went from
- 32:59Speaker 5: about out twenty.
- 33:01Speaker 6: Percent to eighty percent.
- 33:02Speaker 5: It was a difference and the implementation of those results
- 33:09Speaker 5: when a farm D was was involved.
- 33:11Speaker 1: That's significantly.
- 33:12Speaker 5: That was a big part of our study protocol was
- 33:14Speaker 5: to have that feedback loop involved.
- 33:18Speaker 6: With a farm D.
- 33:20Speaker 5: And our study is going through IRB approval now and
- 33:26Speaker 5: we fully intend to implement that as a part of
- 33:30Speaker 5: that but that was an sort of example.
- 33:32Speaker 6: Where we you know, we use we use the experience that.
- 33:36Speaker 5: We learned from having a farm d towards a specific
- 33:40Speaker 5: project that we're that we're doing in the future, and
- 33:43Speaker 5: I think it's going to be a real essential component
- 33:45Speaker 5: of the success of the study.
- 33:48Speaker 1: Oh that's great to hear.
- 33:49Speaker 4: I appreciate you sharing that.
- 33:50Speaker 6: That's awesome.
- 33:52Speaker 1: Yeah, that's a great example because I mean, Jeremy, I'm
- 33:56Speaker 1: sure that we could do a whole podcast as well
- 33:58Speaker 1: on the topic of proving the clinical utility of firmacogenomics
- 34:05Speaker 1: and how critical that research is to justifying two payers
- 34:13Speaker 1: that this test is clinically useful in their population and
- 34:17Speaker 1: the type of research that you just discussed will help
- 34:22Speaker 1: us with that mission. Right. So you know, I think
- 34:28Speaker 1: what you're also saying without saying, is that you know,
- 34:34Speaker 1: farmities play a valuable role in the research and you know,
- 34:39Speaker 1: help improve its utility. Would would you say that's accurate?
- 34:43Speaker 6: Oh?
- 34:43Speaker 5: Absolutely, And again we had we had sort of proven
- 34:47Speaker 5: that to ourselves, yes, without publishing that, and it you know,
- 34:51Speaker 5: it makes just sense on the surface, right, It's it's
- 34:53Speaker 5: sort of confirming something that you probably already know.
- 34:56Speaker 6: You just need to generate that evidence. That's right, and
- 35:00Speaker 6: so we.
- 35:00Speaker 5: Were not surprised when we saw those numbers. I guess
- 35:03Speaker 5: we were a bit surprised in terms of the delta
- 35:05Speaker 5: of how much of an effect it made, but were
- 35:09Speaker 5: certainly wasn't surprised.
- 35:11Speaker 6: There was a help.
- 35:13Speaker 5: You know, another area too, and this is me this
- 35:16Speaker 5: is more speculation. Isn't an area of compliance because you know,
- 35:20Speaker 5: if you think about a lot of molecular tests, especially
- 35:25Speaker 5: like constitutional tests where you're testing for germline variants or carriers.
- 35:30Speaker 5: You know, a lot of those testing and the payers
- 35:33Speaker 5: require this and so, and a lot of professional society
- 35:37Speaker 5: guidelines they require a genetic counseling, right. They want somebody
- 35:41Speaker 5: who's trained to interpret clinical interpretation. They want that feedback
- 35:46Speaker 5: to the physician. And that's not a requirement in the
- 35:50Speaker 5: area of pg X. But I wouldn't be surprised as this.
- 35:55Speaker 5: You know, as this matures, as this area becomes more
- 35:58Speaker 5: and more widespread in hospital systems and clinics, that those
- 36:03Speaker 5: types of recommendations and maybe even requirements could be part.
- 36:08Speaker 6: Of part of the test.
- 36:10Speaker 5: So you know, it is a way to perhaps be
- 36:13Speaker 5: ahead of that. And who knows what happens, you know,
- 36:18Speaker 5: be able to get involved. They certainly have a special
- 36:20Speaker 5: place in their heart for PGX testament and that might
- 36:24Speaker 5: be something that they have an opinion about as well.
- 36:28Speaker 1: Well, I'll just share to boost your speculation or endorse
- 36:31Speaker 1: your speculation when helping a laboratory with their technical assessment,
- 36:39Speaker 1: mod X replied to them, did a pharmacist even look
- 36:44Speaker 1: at this for you?
- 36:47Speaker 5: So?
- 36:49Speaker 1: I think you hit the nail on the head when
- 36:52Speaker 1: you said that payers and the community in general are
- 36:57Speaker 1: going to expect that laboratories involve a farm D with
- 37:02Speaker 1: their farmingco genomics, And I mean that that was priceless
- 37:07Speaker 1: to me. Of course, you know, I wasn't happy that
- 37:11Speaker 1: their assessment was initially denied, but that was a priceless
- 37:16Speaker 1: moment in my in my work was reading that comment. So, yeah,
- 37:24Speaker 1: I think you're absolutely onto something. So if you were
- 37:29Speaker 1: advising other clinical labs, because you know, that's part of
- 37:33Speaker 1: what we want to do is we don't want to
- 37:34Speaker 1: just say, oh, yeah, it's wonderful for a lab to
- 37:39Speaker 1: have a farm D. What do those labs need to
- 37:43Speaker 1: look for when they're leveraging pharmacism? You know, what would
- 37:46Speaker 1: your top recommendations be for, Hey, how do I find
- 37:53Speaker 1: a farm d you know, do they come to you,
- 37:57Speaker 1: do you see them out? You know, how can they
- 38:01Speaker 1: maximize uh, that value the pharmacists can bring when they're
- 38:07Speaker 1: when they're on boarding and bringing this pharmacist on board.
- 38:11Speaker 6: Yeah, so I can share my experience with you.
- 38:14Speaker 5: And we've we've engaged with multiple farm d's and they
- 38:17Speaker 5: came from different they came.
- 38:19Speaker 6: From different sources.
- 38:20Speaker 5: So there are farm d's that are actively looking for
- 38:24Speaker 5: this type of type of right, we're actively looking for
- 38:26Speaker 5: companies and so we've engaged farm ds on a on
- 38:30Speaker 5: a consultancy basis, you know, just as pure consultants too,
- 38:35Speaker 5: and to do many of the things that I talked about,
- 38:38Speaker 5: especially early on, which was help us, help us, you know,
- 38:41Speaker 5: develop our report, give us feedback on what it says
- 38:44Speaker 5: and how it says. What are some markers that we
- 38:46Speaker 5: should really be considering when it comes to the development
- 38:49Speaker 5: of our tests. Not necessarily markers, but what are the drugs,
- 38:52Speaker 5: you know, what are the what are the you know,
- 38:54Speaker 5: the high priority targets when it comes to gene drug relationship.
- 38:59Speaker 5: So there's certainly that and we've done we've gone down
- 39:02Speaker 5: that path. We are fortunate to be have a relationship
- 39:06Speaker 5: with hospital.
- 39:08Speaker 6: Systems systems here in the state.
- 39:11Speaker 5: Many of those hospital systems have their own farm d's,
- 39:13Speaker 5: right farm ds, and some of them may have pg
- 39:20Speaker 5: X experience, I can I can tell you certainly that's
- 39:23Speaker 5: not guaranteed, but I can guarantee you that at least
- 39:25Speaker 5: some of them will be interested in working with you.
- 39:30Speaker 6: So that they can gain that expertise. That's a really
- 39:33Speaker 6: great way to.
- 39:35Speaker 5: Try and work with someone, you know, in the farm
- 39:39Speaker 5: dy areas a lot of and we've also engaged with
- 39:41Speaker 5: pharmacy schools, yes, so there's a lot of rotations and
- 39:47Speaker 5: credits so they can earn just by working with you,
- 39:51Speaker 5: all right, So we've I've had discussions with various pharmacy
- 39:55Speaker 5: schools about that, and I think that's.
- 39:58Speaker 6: Where some of our employment come from as well, you know.
- 40:02Speaker 5: And so I also think that there's just the open
- 40:06Speaker 5: job market sometimes again just recruiting, you know, purely on
- 40:09Speaker 5: a job board and searches, traditional searches, because I think
- 40:14Speaker 5: and you guys can probably speak more to this than
- 40:15Speaker 5: I could, but you know, there's you know, a lot
- 40:18Speaker 5: of consolidation in the pharmacy space when it comes to
- 40:21Speaker 5: detail locations and so and so the traditional job searches
- 40:28Speaker 5: are you know, have been another area where.
- 40:30Speaker 6: We've had some success in as well.
- 40:32Speaker 5: And then we just evaluate our candidates you know, on
- 40:35Speaker 5: a one by one So so that's been a lot
- 40:38Speaker 5: of the the the the you know areas that we've
- 40:43Speaker 5: been able to recruit from. And in terms of the
- 40:47Speaker 5: traits of the farm bese, it's you know a lot
- 40:49Speaker 5: of its instinct. Obviously, I don't look for that genetic
- 40:53Speaker 5: look for that genetic background as a prerequisite because that's
- 40:56Speaker 5: going to weed out a lot of people.
- 40:58Speaker 6: Sure, More about.
- 40:59Speaker 5: Is is this something that they really really have an
- 41:02Speaker 5: interest in and really really like because you know, when
- 41:05Speaker 5: you engage with a physician, you have to believe.
- 41:07Speaker 6: In what you're talking about.
- 41:08Speaker 5: Absolutely, you know, that's so important and absolutely and the
- 41:12Speaker 5: ones who do, you.
- 41:12Speaker 6: Can tell the difference and so and and are also
- 41:16Speaker 6: hungry to learn.
- 41:17Speaker 5: And really like that interaction, like learning that information from
- 41:21Speaker 5: the laboratory teams uh as well as teaching their knowledge.
- 41:26Speaker 6: To the laboratory. Well, so those are the main traits
- 41:29Speaker 6: that I've looked for.
- 41:31Speaker 1: I think those are great insights and you know, not
- 41:34Speaker 1: to plug benaz and eye but we've got a pretty
- 41:38Speaker 1: good handle on the on what's out there and who's
- 41:42Speaker 1: out there, so we can help labs with UH with
- 41:45Speaker 1: that process as well with you know, helping helping you
- 41:49Speaker 1: guys with identifying maybe a farm d that would would
- 41:53Speaker 1: like to work with the lab. So thanks for sharing
- 41:56Speaker 1: that insight with our laboratory listeners. So we're running out
- 42:00Speaker 1: of time. I would love to have you back on
- 42:03Speaker 1: the podcast again and a later date, but for this episode,
- 42:08Speaker 1: we're going to have to wrap up. So I'm going
- 42:10Speaker 1: to ask you. Today's November the sixth, the day after
- 42:15Speaker 1: the election, so it's a pretty big day. So the
- 42:20Speaker 1: million dollar question that everybody in the laboratory industry is
- 42:24Speaker 1: thinking about this morning is how are yesterday's election results?
- 42:30Speaker 1: How do you think it's going to impact the laboratory
- 42:34Speaker 1: industry And you know, specifically the FDA's final rule into
- 42:41Speaker 1: laboratory developed tests, and you know, however else you wanted,
- 42:44Speaker 1: whatever other aspect you want to talk on.
- 42:48Speaker 6: Wow, And I feel like this is a loaded question.
- 42:50Speaker 1: Yes it is.
- 42:52Speaker 5: It is, So I thought about this already, you know,
- 42:56Speaker 5: I woke up this morning thinking about this question because
- 42:59Speaker 5: I think it affects everyone in a laboratory.
- 43:02Speaker 6: So you're right, it does issue their final rule.
- 43:05Speaker 5: They've issued a lot of their their their draft guides,
- 43:08Speaker 5: their final rule. They've had various you know, webinars UH
- 43:13Speaker 5: help laboratories adjust.
- 43:14Speaker 6: To the to these rules.
- 43:16Speaker 5: They've got timeline on a lot of the things that
- 43:18Speaker 5: they want to see and you know, next year, the
- 43:21Speaker 5: year after the year after that.
- 43:23Speaker 6: And the real question in my mind is will all.
- 43:26Speaker 5: This be disrupted, you know, going to happen? Is it
- 43:29Speaker 5: going to go back to where we were before this,
- 43:32Speaker 5: which is you know, sort of this gray murky area
- 43:36Speaker 5: where we're going to have to rely on Congress to
- 43:40Speaker 5: to define what is an l d T and right,
- 43:44Speaker 5: you know, versus an in vitro diagnostic yes, Or will
- 43:49Speaker 5: the administration you know, completely change the FDA's priorities, you know, and.
- 43:57Speaker 6: Go in a different direction. And you know, my crystal
- 44:02Speaker 6: ball is full of mud at this point.
- 44:06Speaker 5: I don't think I have a Powell big enough to
- 44:08Speaker 5: wipe all that mud off, because it is really.
- 44:11Speaker 6: Going to be interesting.
- 44:13Speaker 5: I think, you know, for our for our organization, we're
- 44:18Speaker 5: just going to assume that things are going to be
- 44:19Speaker 5: status quo, that the final rule is an effect that
- 44:21Speaker 5: we're going to march. That'd rather be I'd prepare to
- 44:25Speaker 5: be over prepared than than underprepared.
- 44:27Speaker 1: Yes, I agree, we're going.
- 44:28Speaker 5: To assume under that. You know, we're going to assume
- 44:30Speaker 5: that that. We're going to make the assumption, but it
- 44:33Speaker 5: could completely change. I think it's, uh, you know, a
- 44:38Speaker 5: real wild card here in the works, and I just
- 44:41Speaker 5: have to wait and see.
- 44:43Speaker 6: You know, I wish, I wish I could give a
- 44:44Speaker 6: more definite answer.
- 44:47Speaker 1: Well, if anybody has the answer right now there, they
- 44:51Speaker 1: could probably get a lot of money for that answer.
- 44:56Speaker 1: I don't think the FDA has an answer right right exactly.
- 45:01Speaker 1: So thanks for thanks for giving us your perspective on
- 45:05Speaker 1: this exciting time in the industry. Needless to say, I'm
- 45:10Speaker 1: with you of head Labs. Tell me, oh, I don't
- 45:13Speaker 1: have to worry about that. My test was grandfathered in.
- 45:17Speaker 1: We're good. I don't have to do anything, And I'm like,
- 45:19Speaker 1: whoa hold on, yes you do. So there is there
- 45:27Speaker 1: is no laboratory developed test except one that's already FDA
- 45:31Speaker 1: proved that doesn't have something that they're going to need
- 45:34Speaker 1: to work on to meet the FDA's requirements. So yeah, thanks,
- 45:40Speaker 1: thanks for that. Insight. I'm sure our listeners will appreciate
- 45:43Speaker 1: it very much. Like I mentioned, we're gonna have to
- 45:46Speaker 1: wrap up this episode, so thanks again Jeremy for joining us.
- 45:50Speaker 1: For our listeners that you know want to connect with
- 45:53Speaker 1: you further, what's the best way for them to get
- 45:55Speaker 1: in touch with you?
- 45:57Speaker 5: So I can go to our website genetics dot com.
- 46:01Speaker 5: You can look at our company and some of the
- 46:03Speaker 5: things that we've done. I believe we certainly have an
- 46:07Speaker 5: email and contact information that will.
- 46:10Speaker 6: Get routed to me.
- 46:11Speaker 5: Okay, So any specific questions or anything for that matter, Okay,
- 46:17Speaker 5: just go there and and we'll respond.
- 46:21Speaker 1: All right, So thank you audience for tuning in. I mean,
- 46:26Speaker 1: without our faithful listeners, we wouldn't have such a successful podcast,
- 46:30Speaker 1: and for that we're very grateful. We do a lot
- 46:33Speaker 1: of pg X in here on the Precision Help in
- 46:36Speaker 1: PGS Podcasts PGX Science, Clinical, Application and Business, and we
- 46:43Speaker 1: hope you learned something today and you.
- 46:46Speaker 4: Can listen to all our episodes on pg X for
- 46:49Speaker 4: the number four r X dot com or your preferred
- 46:52Speaker 4: podcast platforms such as Apple.
- 46:54Speaker 1: Podcasts, Spotify, a Podbeam. While you're on the platform, please
- 46:59Speaker 1: leave us a.
- 46:59Speaker 4: Five star review so our sponsors will continue to make
- 47:02Speaker 4: these episodes a podcasts possible.
- 47:05Speaker 6: And we'd love to also hear from you.
- 47:06Speaker 4: What can we teach you, What industry updates do you.
- 47:09Speaker 6: Want to learn about?
- 47:10Speaker 1: Draw us a message on LinkedIn and let us know.
- 47:14Speaker 4: So.
- 47:14Speaker 1: Until next time, here's to precision help and removing the
- 47:18Speaker 1: trial and error from pharmacogenemics.